FDA gives Roche’s Ventana PD-L1 assay approval in lung cancer treatment

Roche's headquarters

The FDA gave its approval to Roche for its Ventana PD-L1 assay to be used as a complementary diagnostic in conjunction with the company’s Tecentriq (atezolizumab) for the treatment of metastatic non-small cell lung cancer.

The PD-L1 (SP142) assay is also indicated to identify patients with urothelial cancer who may benefit from treatment with Tecentriq, the company said.

Roche touts the biomarker assay as the first to evaluate patient PD-L1 expression using both tumor cell and immune cell staining. By determining a patient's PD-L1 expression level, physicians can gain a better insight into the survival benefit that may be achieved from treatment with Tecentriq.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"The approval of the Ventana PD-L1 Assay with Tecentriq underscores Roche's personalized healthcare strategy to provide innovative diagnostic tools that deliver valuable medical information which helps guide treatment decisions for physicians and their patients," Ann Costello, head of Roche’s Tissue Diagnostics division, said in a statement.

According to statistics cited by the company, lung cancer is the leading cause of cancer deaths globally with an annual estimated 12.9% of all new cancer cases and nearly 1.59 million deaths. Non-small cell lung cancer accounts for about 85% of all lung cancer cases, which over the last 30 years has shown the least improvement in survival rates when compared with other cancers.

Roche said t will continue to seek regulatory approval for the Ventana PD-L1 (SP142) assay in combination with Tecentriq for other cancer indications as well as gain regulatory approval for it in other countries.

Read more on

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.